These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 23360924)

  • 21. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass.
    Chan KK; Chen CA; Nam JH; Ochiai K; Wilailak S; Choon AT; Sabaratnam S; Hebbar S; Sickan J; Schodin BA; Sumpaico WW
    Gynecol Oncol; 2013 Feb; 128(2):239-44. PubMed ID: 23063998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer.
    Zhang P; Wang C; Cheng L; Zhang P; Guo L; Liu W; Zhang Z; Huang Y; Ou Q; Wen X; Tian Y
    Medicine (Baltimore); 2015 Dec; 94(52):e2402. PubMed ID: 26717395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
    Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
    Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.
    Terlikowska KM; Dobrzycka B; Witkowska AM; Mackowiak-Matejczyk B; Sledziewski TK; Kinalski M; Terlikowski SJ
    J Ovarian Res; 2016 Jul; 9(1):43. PubMed ID: 27436085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass.
    Goff BA; Agnew K; Neradilek MB; Gray HJ; Liao JB; Urban RR
    Gynecol Oncol; 2017 Nov; 147(2):291-295. PubMed ID: 28860006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic accuracy and cost-effectiveness of different strategies to triage women with adnexal masses: a prospective study.
    Piovano E; Cavallero C; Fuso L; Viora E; Ferrero A; Gregori G; Grillo C; Macchi C; Mengozzi G; Mitidieri M; Pagano E; Zola P
    Ultrasound Obstet Gynecol; 2017 Sep; 50(3):395-403. PubMed ID: 27706929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Ovarian tumor markers of presumed benign ovarian tumors].
    Lahlou N; Brun JL
    J Gynecol Obstet Biol Reprod (Paris); 2013 Dec; 42(8):752-9. PubMed ID: 24210243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RMI and ROMA are equally effective in discriminating between benign and malignant gynecological tumors: A prospective population-based study.
    Liest AL; Omran AS; Mikiver R; Rosenberg P; Uppugunduri S
    Acta Obstet Gynecol Scand; 2019 Jan; 98(1):24-33. PubMed ID: 30216407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic value of CA125, HE4, ROMA and logistic regression model in pelvic mass diagnostics - our experience.
    Michalak M; Gąsiorowska E; Markwitz EN
    Ginekol Pol; 2015 Apr; 86(4):256-61. PubMed ID: 26117983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation in the predictive value of serum human epididymal protein 4 (HE4), cancer antigen 125 (CA 125) and a combination of both in detecting ovarian malignancy.
    Teh BH; Yong SL; Sim WW; Lau KB; Suharjono HN
    Horm Mol Biol Clin Investig; 2018 Jul; 35(1):. PubMed ID: 30063463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
    Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
    Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proofs for implementation of higher HE4 and ROMA index cut-off values in ovarian cancer preoperative stratification.
    Špacir Prskalo Z; Bulić P; Langer S; Gaće M; Puljiz M; Danolić D; Alvir I; Mamić I; Šušnjar L; Mayer L
    J Obstet Gynaecol; 2019 Feb; 39(2):195-201. PubMed ID: 30207507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significance of Serum Human Epididymis Protein 4 and Cancer Antigen 125 in Distinguishing Type I and Type II Epithelial Ovarian Cancers.
    Yanaranop M; Jantarateptewan N; Tiyayon J; Nakrangsee S
    Int J Gynecol Cancer; 2018 Jul; 28(6):1058-1065. PubMed ID: 29975290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses.
    Pitta Dda R; Sarian LO; Barreta A; Campos EA; Andrade LL; Fachini AM; Campbell LM; Derchain S
    BMC Cancer; 2013 Sep; 13():423. PubMed ID: 24044637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of adding progesterone to the Risk of Ovarian Malignancy Algorithm for early stage ovarian cancer detection in patients with a pelvic mass: A single-center case-control study.
    Pitynski K; Sporek A; Lipinska I; Banas T; Ludwin A; Bałajewicz-Nowak M
    Taiwan J Obstet Gynecol; 2015 Dec; 54(6):766-72. PubMed ID: 26701000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
    Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
    Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Borderline ovarian tumors and diagnostic dilemma of intraoperative diagnosis: could preoperative He4 assay and ROMA score assessment increase the frozen section accuracy? A multicenter case-control study.
    Gizzo S; Berretta R; Di Gangi S; Guido M; Zanni GC; Franceschetti I; Quaranta M; Plebani M; Nardelli GB; Patrelli TS
    Biomed Res Int; 2014; 2014():803598. PubMed ID: 25431767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm.
    Van Gorp T; Cadron I; Despierre E; Daemen A; Leunen K; Amant F; Timmerman D; De Moor B; Vergote I
    Br J Cancer; 2011 Mar; 104(5):863-70. PubMed ID: 21304524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer.
    Ortiz-Muñoz B; Aznar-Oroval E; García García A; Covisa Peris A; Perez Ballestero P; Sanchez Yepes M; Garcia Lozano T; Illueca Ballester C; García Garcia E
    Tumour Biol; 2014 Jul; 35(7):7249-58. PubMed ID: 24771264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.
    Li F; Tie R; Chang K; Wang F; Deng S; Lu W; Yu L; Chen M
    BMC Cancer; 2012 Jun; 12():258. PubMed ID: 22712526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.